I think it is reasonable to treat this as a proxy for the state of the evidence, because lots ofAIpolicypeople specifically praised it as a good and thoughtful paper on policy.
All four of those AI policy people are coauthors on the paper—that does not seem like good evidence that the paper is widely considered good and thoughtful, and therefore a good proxy (though I think it probably is an ok proxy).
(disclaimer: one of the coauthors) Also, none of the linked comments by the coauthors actually praise the paper as good and thoughtful? They all say the same thing, which is “pleased to have contributed” and “nice comment about the lead author” (a fairly early-career scholar who did lots and lots of work and was good to work with). I called it “timely”, as the topic of open-sourcing was very much live at the time.
(FWIW, I think this post has valid criticism re: the quality of the biorisk literature cited and the strength with which the case was conveyed; and I think this kind of criticism is very valuable and I’m glad to see it).
All four of those AI policy people are coauthors on the paper—that does not seem like good evidence that the paper is widely considered good and thoughtful, and therefore a good proxy (though I think it probably is an ok proxy).
(disclaimer: one of the coauthors) Also, none of the linked comments by the coauthors actually praise the paper as good and thoughtful? They all say the same thing, which is “pleased to have contributed” and “nice comment about the lead author” (a fairly early-career scholar who did lots and lots of work and was good to work with). I called it “timely”, as the topic of open-sourcing was very much live at the time.
(FWIW, I think this post has valid criticism re: the quality of the biorisk literature cited and the strength with which the case was conveyed; and I think this kind of criticism is very valuable and I’m glad to see it).